Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia
- Conditions
- Childhood Diffuse Large Cell LymphomaChildhood Immunoblastic Large Cell LymphomaRecurrent Childhood Large Cell LymphomaB-cell Childhood Acute Lymphoblastic LeukemiaL3 Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaChildhood Burkitt LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Childhood Small Noncleaved Cell Lymphoma
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 82
- Registration Number
- NCT00058461
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2012-06-01
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 44
- Registration Number
- NCT00058292
- Locations
- 🇺🇸
Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
🇺🇸Hematology-Oncology Associates of Illinois, Chicago, Illinois, United States
🇺🇸Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 140
- Registration Number
- NCT00057837
- Locations
- 🇺🇸
Elkhart General Hospital, Elkhart, Indiana, United States
🇺🇸Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States
🇺🇸St. Luke's Regional Medical Center, Sioux City, Iowa, United States
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
- Conditions
- Childhood Immunoblastic Large Cell LymphomaChildhood Diffuse Large Cell LymphomaStage I Childhood Small Noncleaved Cell LymphomaStage II Childhood Large Cell LymphomaStage II Childhood Small Noncleaved Cell LymphomaStage IV Childhood Small Noncleaved Cell LymphomaStage I Childhood Large Cell LymphomaStage III Childhood Large Cell LymphomaStage IV Childhood Large Cell LymphomaUntreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- Drug: doxorubicin hydrochlorideDrug: cyclophosphamideDrug: methotrexateDrug: leucovorin calciumDrug: rasburicaseDrug: prednisoneDrug: methylprednisoloneBiological: filgrastimBiological: rituximabDrug: cytarabineDrug: etoposideDrug: vincristine sulfateDrug: hydrocortisone sodium succinateOther: laboratory biomarker analysis
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2014-09-19
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 97
- Registration Number
- NCT00057811
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00054665
- Locations
- 🇺🇸
Roswell Parck Cancer Institute, Buffalo, New York, United States
🇺🇸National Cancer Institute (NCI), Bethesda, Maryland, United States
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-07-24
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 34
- Registration Number
- NCT00054327
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2021-05-18
- Target Recruit Count
- 392
- Registration Number
- NCT00053768
- Locations
- 🇩🇪
Regional Hospital Traunstein, Traunstein, Germany
🇩🇪Hospital Tutzing, Tutzing, Germany
🇩🇪Krankenhaus Der Barmherzigen Brueder, Trier, Germany
Chemotherapy and Stem Cell Transplantation in Treating Children With Central Nervous System Cancer
- Conditions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2011-03-01
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00053118
- Locations
- 🇺🇸
St. Louis Children's Hospital, Saint Louis, Missouri, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
- Conditions
- Ovarian Embryonal CarcinomaStage IIC Ovarian Germ Cell TumorStage III Malignant Testicular Germ Cell TumorStage IIIA Ovarian Germ Cell TumorChildhood Embryonal TumorChildhood Extracranial Germ Cell TumorChildhood Extragonadal Germ Cell TumorChildhood Malignant Testicular Germ Cell TumorChildhood TeratomaOvarian Yolk Sac Tumor
- Interventions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 302
- Registration Number
- NCT00053352
- Locations
- 🇺🇸
West Virginia University Charleston, Charleston, West Virginia, United States
🇺🇸Geisinger Medical Center, Danville, Pennsylvania, United States
🇺🇸Children's Hospital Central California, Madera, California, United States
Combination Chemotherapy and Imatinib Mesylate in Treating Children With Relapsed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-10-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 126
- Registration Number
- NCT00049569
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.